Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01121
|
|||||
Drug Name |
Taurocholic acid
|
|||||
Synonyms |
2-((3-alpha,7-alpha,12-alpha-Trihydroxy-24-oxo-5-be ta-cholan-24-yl)amino)ethanesulfonic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid 24-taurine; 81-24-3; Acidum cholatauricum; C26H45NO7S; Cholaic acid; Cholic acid taurine conjugate; Cholyltaurine; EINECS 201-336-2; Ethanesulfonic acid, 2-(((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl)amino)-; HSDB 832; N-Choloyltaurine; NSC 25505; NSC25505; TAUROCHOLIC ACID; Taurine Cholate; Taurine, N-choloyl-; Taurocholate; Taurocholic acid; UNII-5E090O0G3Z; [3H]taurocholic acid
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Type 2 diabetes [ICD11: 5A11] | Terminated | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C26H45NO7S
|
|||||
Canonical SMILES |
CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C
|
|||||
InChI |
InChI=1S/C26H45NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-/m1/s1
|
|||||
InChIKey |
WBWWGRHZICKQGZ-HZAMXZRMSA-N
|
|||||
CAS Number |
CAS 81-24-3
|
|||||
Pharmaceutical Properties | Molecular Weight | 515.7 | Topological Polar Surface Area | 153 | ||
Heavy Atom Count | 35 | Rotatable Bond Count | 7 | |||
Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 7 | |||
XLogP |
2.2
|
|||||
PubChem CID | ||||||
PubChem SID |
103512877
, 104312745
, 119526221
, 125311155
, 125311164
, 134972658
, 135750992
, 137102321
, 137202600
, 138724705
, 144080928
, 14717827
, 15805741
, 160854684
, 162224002
, 163138205
, 164779365
, 17422067
, 176484548
, 178101267
, 178101268
, 179323898
, 198948969
, 224772447
, 226395830
, 252497719
, 29225628
, 4266393
, 47439969
, 49748546
, 50065243
, 50397873
, 53789715
, 57323632
, 605316
, 8138084
, 8154316
, 828139
, 841389
, 86672
, 92309274
, 93167213
|
|||||
ChEBI ID |
CHEBI:28865
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | ASBT | Transporter Info | Apical sodium-dependent bile acid transporter | Substrate | [2] | |
BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
BSEP | Transporter Info | Bile salt export pump | Substrate | [4] | ||
MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [5] | ||
MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [6] | ||
NTCP | Transporter Info | Sodium/taurocholate cotransporting polypeptide | Substrate | [7] | ||
OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [8] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [9] | ||
OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [10] | ||
OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [11] | ||
OATP4A1 | Transporter Info | Organic anion transporting polypeptide 4A1 | Substrate | [12] | ||
OSTalpha | Transporter Info | Organic solute transporter subunit alpha | Substrate | [13] | ||
OSTbeta | Transporter Info | Organic solute transporter subunit beta | Substrate | [13] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | ASBT | Transporter Info | Km = 9.4 microM | Human embryonic kidney cells (HEK293)-ASBT | [2] | |
ASBT | Transporter Info | Km = 13.3 microM | Monkey kidney fibroblast-like cell (COS)1-ASBT | [14] | ||
BSEP | Transporter Info | Km = 4.25 microM | High five cells-BSEP | [15] | ||
NTCP | Transporter Info | Km = 7.9 microM | Human cervical cancer cell line (Hela)-NTCP | [7] | ||
NTCP | Transporter Info | Km = 6.2 microM | Oocytes-NTCP | [16] | ||
OATP1A2 | Transporter Info | Km = 15.9 microM | Human embryonic kidney cells (HEK293)-OATP1A2 | [8] | ||
OATP1A2 | Transporter Info | Km = 64 microM | Human liver cancer cells (HepG2)-OATP1A2 | [17] | ||
OATP1A2 | Transporter Info | Km = 60 microM | Oocytes-OATP1A2 | [18] | ||
OATP1B1 | Transporter Info | Km = 33.8 microM | Human embryonic kidney cells (HEK293)-OATP1B1 | [19] | ||
OATP1B1 | Transporter Info | Km = 13.6 microM | Oocytes-OATP1B1 | [9] | ||
OATP2B1 | Transporter Info | Km = 71.8 microM | Human embryonic kidney cells (HEK293)-OATP2B1 | [11] | ||
OATP4A1 | Transporter Info | Km = 14.9 microM | Oocytes-OATP4A1 | [12] | ||
References | ||||||
1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033000) | |||||
2 | Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24. | |||||
3 | Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83. | |||||
4 | Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8. | |||||
5 | Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000. | |||||
6 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
7 | Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9. | |||||
8 | Identification of multiple binding sites for substrate transport in bovine organic anion transporting polypeptide 1a2. Drug Metab Dispos. 2013 Mar;41(3):602-7. | |||||
9 | Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63. | |||||
10 | Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65. | |||||
11 | Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. | |||||
12 | Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12. | |||||
13 | Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. | |||||
14 | Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. | |||||
15 | The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. | |||||
16 | Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31. | |||||
17 | Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology. 1996 May;23(5):1053-60. | |||||
18 | Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82. | |||||
19 | A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.